Treat and Reduce Obesity Act of 2025
- Bill Number
- H.R. 4231
- Origin Chamber
- House
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-06-27: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Last Updated
- 2026-07-01T08:09:11Z
AI-Generated Summary
Purpose of the Legislation
The "Treat and Reduce Obesity Act of 2025" aims to improve Medicare coverage for obesity prevention and treatment by expanding access to behavioral therapies and medications. It addresses the growing obesity epidemic among older adults, particularly Medicare beneficiaries, by coordinating federal health programs and reducing barriers to care.
Key Provisions
- Findings (Section 2): The bill outlines Congress's recognition of obesity as a major public health issue, citing statistics such as:
- About 41% of adults aged 60+ had obesity in 2015–2016, affecting over 27 million people.
- Obesity contributes to 300,000 deaths annually and increases risks for conditions like heart disease, diabetes, and certain cancers.
- Among Medicare beneficiaries, obesity rates have nearly doubled multiple times since 1987, driving up costs to $50 billion in 2014, with obese beneficiaries costing $2,018 more per year than those at healthy weights.
- Projections indicate nearly 47% of Medicare beneficiaries aged 65+ could have obesity by 2030 if trends continue.
- Expansion of Providers for Intensive Behavioral Therapy (Section 3): Amends the Social Security Act to allow Medicare to cover obesity-focused behavioral therapy (counseling to change habits like diet and exercise) provided by a broader range of professionals, including:
- Non-primary care physicians.
- Physician assistants, nurse practitioners, clinical nurse specialists, clinical psychologists, registered dietitians, or nutrition professionals.
- Approved community-based lifestyle counseling programs.
- Therapy must be referred by and coordinated with a primary care physician or practitioner, delivered in approved settings (e.g., offices, hospitals, or privacy-compliant community sites), and include communication of treatment plans back to the referrer.
- Coverage of Obesity Medications Under Medicare Part D (Section 4): Removes the current exclusion for prescription drugs used to treat obesity or manage weight loss in overweight individuals with related health issues (e.g., comorbidities like high blood pressure). This applies to plan years starting 2 years after enactment.
- Reporting Requirements (Section 5): The Secretary of Health and Human Services (HHS) must submit reports to Congress 1 year after enactment and every 2 years thereafter, detailing implementation steps and recommendations for better coordination of obesity-related programs across HHS and other federal agencies, including research, clinical care, and provider-patient interactions.
Significant Changes to Existing Law
- Provider Expansion: Previously, Medicare's intensive behavioral therapy for obesity was limited to primary care physicians and certain practitioners. This bill broadens eligibility to additional providers and community programs, promoting a team-based approach while requiring physician oversight.
- Drug Coverage: Medicare Part D currently excludes drugs primarily for weight loss or obesity treatment (similar to exclusions for cosmetics or fertility aids). The amendment lifts this for obesity-specific uses, potentially allowing coverage of FDA-approved medications like certain appetite suppressants or metabolic treatments, but only when tied to defined obesity or overweight with comorbidities.
- No changes to overall Medicare eligibility or funding mechanisms are introduced; the focus is on coverage rules within existing Title XVIII (Medicare).
Potential Impacts
- On Government Agencies: HHS will need to update Medicare guidelines, approve new providers and programs, and produce ongoing reports, increasing administrative workload but fostering inter-agency coordination on obesity initiatives. Long-term, it could reduce Medicare spending on obesity-related chronic conditions by enabling earlier interventions.
- On Citizens: Medicare beneficiaries (primarily those 65+ or with disabilities) gain easier access to therapies and drugs, potentially improving health outcomes, life expectancy, and quality of life for the estimated 27+ million obese older adults. However, it may not immediately lower out-of-pocket costs, as Part D plans vary.
- On International Relations: No direct impacts; the bill is domestic-focused on U.S. public health and Medicare.
Main Stakeholders Affected
- Medicare Beneficiaries: Older adults and those with chronic conditions, who stand to benefit from expanded treatment options.
- Healthcare Providers: Physicians, nurses, psychologists, dietitians, and community programs, who gain reimbursement opportunities but must adhere to referral and coordination rules.
- Pharmaceutical Industry: Companies producing obesity medications, which could see increased Medicare prescriptions and revenue.
- Federal Agencies: HHS (lead implementation), Centers for Medicare & Medicaid Services (CMS) for coverage rules, and other agencies involved in obesity research/prevention.
- Taxpayers and Congress: Indirectly affected through potential shifts in Medicare expenditures, with reports aiding future policy decisions.
Notable Legal, Constitutional, or Political Implications
- Legal: Strengthens Medicare's role in preventive care under the Social Security Act without altering core entitlement structures. Ensures compliance with privacy laws (e.g., HIPAA) for community settings. The 2-year delay for drug coverage allows time for regulatory adjustments and FDA alignment on drug approvals.
- Constitutional: No apparent challenges; it falls within Congress's authority to regulate interstate commerce and spending for public health (e.g., via the Spending Clause).
- Political: Highlights bipartisan support (introduced by a diverse group of representatives) for addressing obesity as a non-partisan crisis, potentially setting precedent for expanding Medicare to lifestyle interventions. Could influence debates on healthcare costs and preventive medicine, but raises questions about fiscal sustainability given rising obesity projections.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (82)
Rep. Ruiz, Raul [D-CA-25], Rep. Miller-Meeks, Mariannette [R-IA-1], Rep. Moore, Gwen [D-WI-4], Rep. Panetta, Jimmy [D-CA-19], Rep. Fitzpatrick, Brian K. [R-PA-1], Rep. Boyle, Brendan F. [D-PA-2], Rep. Carey, Mike [R-OH-15], Rep. Thanedar, Shri [D-MI-13], Rep. Cohen, Steve [D-TN-9], Del. Norton, Eleanor Holmes [D-DC-At Large], Rep. Tlaib, Rashida [D-MI-12], Rep. Schweikert, David [R-AZ-1], Rep. Larson, John B. [D-CT-1], Rep. Bacon, Don [R-NE-2], Rep. Figures, Shomari [D-AL-2], Rep. Thompson, Bennie G. [D-MS-2], Rep. Nadler, Jerrold [D-NY-12], Rep. Crow, Jason [D-CO-6], Rep. Beyer, Donald S. [D-VA-8], Rep. Mrvan, Frank J. [D-IN-1], Rep. Sewell, Terri A. [D-AL-7], Rep. Yakym, Rudy [R-IN-2], Rep. Conaway, Herbert C. [D-NJ-3], Rep. Gonzalez, Vicente [D-TX-34], Rep. Waters, Maxine [D-CA-43], Rep. Carbajal, Salud O. [D-CA-24], Rep. Suozzi, Thomas R. [D-NY-3], Rep. Foster, Bill [D-IL-11], Rep. De La Cruz, Monica [R-TX-15], Rep. Matsui, Doris O. [D-CA-7], Rep. Gottheimer, Josh [D-NJ-5], Rep. Vindman, Eugene Simon [D-VA-7], Rep. Bonamici, Suzanne [D-OR-1], Rep. McCollum, Betty [D-MN-4], Rep. Meng, Grace [D-NY-6], Rep. Watson Coleman, Bonnie [D-NJ-12], Rep. Hern, Kevin [R-OK-1], Rep. Valadao, David G. [R-CA-22], Rep. McClain Delaney, April [D-MD-6], Rep. Budzinski, Nikki [D-IL-13], Rep. Barragán, Nanette Diaz [D-CA-44], Rep. DelBene, Suzan K. [D-WA-1], Rep. Rouzer, David [R-NC-7], Rep. Pocan, Mark [D-WI-2], Rep. Davis, Donald G. [D-NC-1], Rep. Fletcher, Lizzie [D-TX-7], Rep. Lynch, Stephen F. [D-MA-8], Rep. Craig, Angie [D-MN-2], Rep. Swalwell, Eric [D-CA-14], Rep. Carter, Troy A. [D-LA-2] and 32 more
Recent Actions
- 2025-06-27: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2025-06-27: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2025-06-27: Introduced in House
- 2025-06-27: Introduced in House
Bill Versions
- Treat and Reduce Obesity Act of 2025 — issued 2025-06-27 — PDF (6 pages)